June 17 (Reuters) - Creso Pharma Ltd (CPH) :
- CRESO PHARMA AND RED LIGHT HOLLAND HAVE ENTERED INTO A DEFINITIVE AGREEMENT TO MERGE THEIR BUSINESSES AND CREATE HIGHBRID LAB
- HIGHBRID LAB IS EXPECTED TO HAVE AN IMPLIED PRO FORMA EQUITY VALUE OF A$371 MILLION
- BRUCE LINTON EXPECTED TO JOIN AS NON-EXECUTIVE CHAIRMAN OF HIGHBRID LAB'S BOARD OF DIRECTORS
- ONCE MERGED, HIGHBRID LAB TO COMMENCE SELLING ITS ANIMAL AND HUMAN CBD PRODUCTS WITHIN USA
- HIGHBRID LAB WILL TRADE ON CANADIAN SECURITIES EXCHANGE UNDER TICKER SYMBOL 'TRIP'
News: CPH Creso Pharma And Red Light Holland Entered Definitive Agreement To Merge Their Businesses
Add to My Watchlist
What is My Watchlist?